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Background & Aims: The Notch signaling pathway is activated in
leukemia and solid tumors (such as lung cancer), but little is known
about its role in liver cancer.
Methods: The intracellular domain of Notch was conditionally
expressed in hepatoblasts and their progeny (hepatocytes and cho-
langiocytes) in mice. This was achieved through Cre expression under
the control of an albumin and a-fetoprotein (AFP) enhancer and pro-
moter (AFP-Notch intracellular domain [NICD]). We used compara-
tive functional genomics to integrate transcriptome data from AFP-
NICD mice and human hepatocellular carcinoma (HCC) samples
(n = 683). A Notch gene signature was generated using the nearest
template prediction method.
Results: AFP-NICD mice developed HCC with 100% penetrance when
they were 12 months old. Activation of Notch signaling correlated
with activation of three promoters of insulin-like growth factor 2;
these processes appeared to contribute to hepatocarcinogenesis.
Comparative functional genomic analysis identiﬁed a signature of
Notch activation in 30% of HCC samples from patients. These samples
had altered expression in Notch pathway genes and activation of
insulin-like growth factor signaling, despite a low frequency of
mutations in regions of NOTCH1 associated with cancer. Blocking
Notch signaling in liver cancer cells with the Notch activation
signature using c-secretase inhibitors or by expressing a dominant
negative form of mastermind-like 1 reduced their proliferation
in vitro.Journal of Hepatology 20
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The Notch signaling cascade is a highly evolutionary con-
served pathway controlling cell differentiation, proliferation,
apoptosis, and ultimately cell fate. It is one of the few main hubs
in a developmental network, along with Ras/MAP, Hedgehog,
Wnt, TGFb, and JAK/STAT pathways, and determines a binary cell
fate in cells with equal developmental potential [1]. The core
framework of the pathway consists of interaction between Notch
receptors (i.e., Notch1 through Notch4) with ﬁve ligands (i.e., Jag-
ged1, Jagged2, and Delta-like ligands 1, 3, and 4) with subsequent
activation of downstream target genes. The key event in Notch
receptor activation is its intramembrane proteolysis, which
requires direct contact between the ligand bearing cell and the
receptor expressing cell, and involves proteolytic processing of
Notch, causing release and translocation to the nucleus of its
intracellular domain (NICD). Within the nucleus, NICD interacts
with transcriptional regulators, displaces transcriptional
co-repressors, recruits co-activators, and, ﬁnally, executes tran-
scriptional activation of target genes. Many target genes of the
pathway, such as the basic helix-loop-helix proteins from Hairy
enhancer of split (Hes) or Hairy related (Hey or Hrt) family, are
universal for different cell types; while others are tissue speciﬁc,
with the best example being the SRY-related transcriptional fac-
tor SOX9, which is essential for normal biliary system formation
[2]. Notch-dependent cell fate events occur over relatively short
developmental life spans and, despite ‘‘at a glance’’ simplicity of
the signaling, have to occur with stalking accuracy in an efﬁcient
manner. Mistakes in this high-ﬁdelity process lead to pathology.
The classic example of pathway dysregulation in the liver is Ala-
gille syndrome characterized by a defective biliary tube forma-
tion due to mutation in Notch ligand Jagged1.
Notch dysregulation has also been implicated in oncogenesis.
Thus, Notch dysregulation occurs in acute T-cell lymphoblastic
leukemia where mutations in C-terminal PEST domain of Notch1
lead to constitutive activation of the pathway [3]. However, the
role of Notch signaling in solid tumors is still emerging, and in
liver malignancies, tumor suppressive versus tumor promoting
action of Notch signaling has been a subject of debate [4–6]. In13 vol. 58 j 1244–1245
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Fig. 1. Liver cancer phenotype in Notch-driven liver carcinogenesis depends
on an oncogenic background. Notch contributes to the development of HCC and
cholangiocarcinoma; we propose it is the oncogenic background (A or B), rather
than Notch itself, that determines the malignant cellular phenotype.
JOURNAL OF HEPATOLOGYcholangiocarcinoma oncogenesis, two recent studies have dem-
onstrated that upon Notch dysregulation, adult hepatocytes can
undergo an oncogenic phenotypic switch to acquire characteris-
tics typically attributed to cholangiocarcinoma, including CK19
and SOX19 expression. Indeed, using a mouse model of hepato-
cyte fate tracing, Fan et al. have demonstrated that Notch and
AKT signaling pathways cooperate to transform fully differenti-
ated normal adult hepatocytes into precursors of highly aggres-
sive intrahepatic cholangiocarcinoma [7], while Sekiya et al.,
employing a mouse model of intrahepatic cholangiocarcinoma,
where hepatocytes and cholangiocytes were labeled with herita-
ble reporters, have shown that cholangiocarcinoma cells were
also derived from a Notch-driven conversion of adult hepatocytes
[8].
Recently, Villanueva et al. took a step forward and aimed at
elucidating the role of the Notch signaling cascade in hepatocel-
lular carcinoma (HCC), utilizing a genetically engineered mouse
model and comparative functional genomics [9]. The group
reported that aberrant Notch signaling throughout liver develop-
ment and into adulthood promotes hepatocyte carcinogenesis in
a mouse model. They identiﬁed a molecular Notch signature in
one third of human HCCs of different etiologies. Pathologic exam-
ination of HCCs associated with Notch signaling upregulation
demonstrated a subset of tumors enriched with cells positive
for CK19, a marker of biliary epithelial cells. The prior and later
data raise the question: how can one pathway, Notch signaling,
contribute to two different liver cell cancers, HCC and cholangio-
carcinoma? This could be explained by a concept of dysregulated
Notch signaling in hepatic progenitor cells (HPC), which are able
to differentiate into either hepatocytes or cholangiocytes, as
nicely reviewed by Strazzabosco et al. [10]. This fate-determina-
tion of the bipotent HPC into hepatocytes or cholangiocytes in
response to an injury can be directed by the inﬂammatory cells
in the microenvironment (e.g., macrophages-derived signals)
[11]. Presumably, the inﬂammatory cells in chronic liver disease
could inﬂuence the oncogenic transformation of HPC into either
hepatocellular or cholangiocellular carcinoma. However, we want
to pose another rather provocative question: can the different
phenotypes of cells observed in HCCs with Notch signature reﬂect
the ability of mature hepatocytes to acquire diverse ‘‘phenotypic
masks?’’ (Fig. 1). We further propose that tumors can be catego-
rized into a molecular cancer genotype, irrespective of histologi-
cal subtypes. In the Villanueva et al. study, this would be a Notch-
driven genotype causing an HCC phenotype. In other studies, it
would be a Notch-driven genotype, with a predominant cholangi-Journal of Hepatology 2013ocarcinoma phenotype. This concept suggests that cross-talk
between oncogenic signaling pathways determines the malig-
nant cells histological phenotype. In fact, Villanueva et al. also
demonstrated co-activation of IGF, AKT, and mTOR pathways in
Notch signature positive HCCs. In contrast, dysregulation of
Notch signaling in another oncogenic context may drive a cholan-
giocarcinoma phenotype.
In summary, based on the topical and comprehensive study of
Villanueva et al., we can conclude that Notch signaling cascade is
activated in a subset of human HCCs and also, from the work of
others, in cholangiocarcinoma. With current advances in biotech-
nologies, it is becoming possible to classify tumors based on their
predominant oncogenic driver rather on their histological pheno-
type. Perhaps Notch targeted therapies should be applied to both
HCC and cholangiocarcinoma in a distinct molecular cancer geno-
type, termed ‘‘Notch-associated liver cancer.’’Financial support
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